Cargando…
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of conce...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110310/ https://www.ncbi.nlm.nih.gov/pubmed/35654046 http://dx.doi.org/10.1016/j.xcrm.2022.100651 |
_version_ | 1784709075805667328 |
---|---|
author | Garcia-Valtanen, Pablo Hope, Christopher M. Masavuli, Makutiro G. Yeow, Arthur Eng Lip Balachandran, Harikrishnan Mekonnen, Zelalem A. Al-Delfi, Zahraa Abayasingam, Arunasingam Agapiou, David Stella, Alberto Ospina Aggarwal, Anupriya Bouras, George Gummow, Jason Ferguson, Catherine O’Connor, Stephanie McCartney, Erin M. Lynn, David J. Maddern, Guy Gowans, Eric J. Reddi, Benjamin A.J. Shaw, David Kok-Lim, Chuan Beard, Michael R. Weiskopf, Daniela Sette, Alessandro Turville, Stuart G. Bull, Rowena A. Barry, Simon C. Grubor-Bauk, Branka |
author_facet | Garcia-Valtanen, Pablo Hope, Christopher M. Masavuli, Makutiro G. Yeow, Arthur Eng Lip Balachandran, Harikrishnan Mekonnen, Zelalem A. Al-Delfi, Zahraa Abayasingam, Arunasingam Agapiou, David Stella, Alberto Ospina Aggarwal, Anupriya Bouras, George Gummow, Jason Ferguson, Catherine O’Connor, Stephanie McCartney, Erin M. Lynn, David J. Maddern, Guy Gowans, Eric J. Reddi, Benjamin A.J. Shaw, David Kok-Lim, Chuan Beard, Michael R. Weiskopf, Daniela Sette, Alessandro Turville, Stuart G. Bull, Rowena A. Barry, Simon C. Grubor-Bauk, Branka |
author_sort | Garcia-Valtanen, Pablo |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of concern (VOCs) in mild-COVID-19 convalescents at 12 months after infection with ancestral virus. In this cohort, ancestral, receptor-binding domain (RBD)-specific antibody and circulating memory B cell levels are conserved in most individuals, and yet serum neutralization against live B.1.1.529 (Omicron) is completely abrogated and significantly reduced for other VOCs. Likewise, ancestral SARS-CoV-2-specific memory T cell frequencies are maintained in >50% of convalescents, but the cytokine response in these cells to mutated spike epitopes corresponding to B.1.1.529 and B.1.351 (Beta) VOCs were impaired. These results indicate that increased antigen variability in VOCs impairs humoral and spike-specific T cell immunity post-infection, strongly suggesting that COVID-19 convalescents are vulnerable and at risk of re-infection with VOCs, thus stressing the importance of vaccination programs. |
format | Online Article Text |
id | pubmed-9110310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91103102022-05-17 SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents Garcia-Valtanen, Pablo Hope, Christopher M. Masavuli, Makutiro G. Yeow, Arthur Eng Lip Balachandran, Harikrishnan Mekonnen, Zelalem A. Al-Delfi, Zahraa Abayasingam, Arunasingam Agapiou, David Stella, Alberto Ospina Aggarwal, Anupriya Bouras, George Gummow, Jason Ferguson, Catherine O’Connor, Stephanie McCartney, Erin M. Lynn, David J. Maddern, Guy Gowans, Eric J. Reddi, Benjamin A.J. Shaw, David Kok-Lim, Chuan Beard, Michael R. Weiskopf, Daniela Sette, Alessandro Turville, Stuart G. Bull, Rowena A. Barry, Simon C. Grubor-Bauk, Branka Cell Rep Med Article Coronavirus disease 2019 (COVID-19) convalescents living in regions with low vaccination rates rely on post-infection immunity for protection against re-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluate humoral and T cell immunity against five variants of concern (VOCs) in mild-COVID-19 convalescents at 12 months after infection with ancestral virus. In this cohort, ancestral, receptor-binding domain (RBD)-specific antibody and circulating memory B cell levels are conserved in most individuals, and yet serum neutralization against live B.1.1.529 (Omicron) is completely abrogated and significantly reduced for other VOCs. Likewise, ancestral SARS-CoV-2-specific memory T cell frequencies are maintained in >50% of convalescents, but the cytokine response in these cells to mutated spike epitopes corresponding to B.1.1.529 and B.1.351 (Beta) VOCs were impaired. These results indicate that increased antigen variability in VOCs impairs humoral and spike-specific T cell immunity post-infection, strongly suggesting that COVID-19 convalescents are vulnerable and at risk of re-infection with VOCs, thus stressing the importance of vaccination programs. Elsevier 2022-05-17 /pmc/articles/PMC9110310/ /pubmed/35654046 http://dx.doi.org/10.1016/j.xcrm.2022.100651 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Garcia-Valtanen, Pablo Hope, Christopher M. Masavuli, Makutiro G. Yeow, Arthur Eng Lip Balachandran, Harikrishnan Mekonnen, Zelalem A. Al-Delfi, Zahraa Abayasingam, Arunasingam Agapiou, David Stella, Alberto Ospina Aggarwal, Anupriya Bouras, George Gummow, Jason Ferguson, Catherine O’Connor, Stephanie McCartney, Erin M. Lynn, David J. Maddern, Guy Gowans, Eric J. Reddi, Benjamin A.J. Shaw, David Kok-Lim, Chuan Beard, Michael R. Weiskopf, Daniela Sette, Alessandro Turville, Stuart G. Bull, Rowena A. Barry, Simon C. Grubor-Bauk, Branka SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents |
title | SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents |
title_full | SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents |
title_fullStr | SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents |
title_full_unstemmed | SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents |
title_short | SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents |
title_sort | sars-cov-2 omicron variant escapes neutralizing antibodies and t cell responses more efficiently than other variants in mild covid-19 convalescents |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110310/ https://www.ncbi.nlm.nih.gov/pubmed/35654046 http://dx.doi.org/10.1016/j.xcrm.2022.100651 |
work_keys_str_mv | AT garciavaltanenpablo sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT hopechristopherm sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT masavulimakutirog sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT yeowarthurenglip sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT balachandranharikrishnan sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT mekonnenzelalema sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT aldelfizahraa sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT abayasingamarunasingam sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT agapioudavid sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT stellaalbertoospina sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT aggarwalanupriya sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT bourasgeorge sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT gummowjason sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT fergusoncatherine sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT oconnorstephanie sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT mccartneyerinm sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT lynndavidj sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT maddernguy sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT gowansericj sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT reddibenjaminaj sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT shawdavid sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT koklimchuan sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT beardmichaelr sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT weiskopfdaniela sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT settealessandro sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT turvillestuartg sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT bullrowenaa sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT barrysimonc sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents AT gruborbaukbranka sarscov2omicronvariantescapesneutralizingantibodiesandtcellresponsesmoreefficientlythanothervariantsinmildcovid19convalescents |